INCY - Incyte Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
84.15
+0.73 (+0.88%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close83.42
Open82.04
Bid75.00 x 1100
Ask84.99 x 900
Day's Range82.45 - 84.25
52 Week Range57.00 - 96.33
Volume1,904,402
Avg. Volume1,627,874
Market Cap17.908B
Beta (3Y Monthly)1.13
PE Ratio (TTM)165.00
EPS (TTM)0.51
Earnings DateFeb 13, 2019 - Feb 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est88.53
Trade prices are not sourced from all markets
  • Incyte (INCY) Q4 2018 Earnings Conference Call Transcript
    Motley Fool2 days ago

    Incyte (INCY) Q4 2018 Earnings Conference Call Transcript

    INCY earnings call for the period ending December 31, 2018.

  • Highly Rated Biotech Turns Profitable — But Earnings Lag Estimates
    Investor's Business Daily2 days ago

    Highly Rated Biotech Turns Profitable — But Earnings Lag Estimates

    Incyte earnings lagged expectations in the fourth quarter, but the company turned around from a year-earlier loss as sales beat estimates — prodding Incyte stock to rise Thursday.

  • Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat
    Zacks2 days ago

    Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat

    Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.

  • Biotech Hedge Fund Bailed on Drugmaker Before Its Depression Treatment Scored
    Bloomberg2 days ago

    Biotech Hedge Fund Bailed on Drugmaker Before Its Depression Treatment Scored

    Baker Bros., which was among the top 20 holders of the biotech stock at the end of September, sold its final 567,497 shares by the end of 2018, according to a regulatory filing this week. Baker Bros. didn’t immediately respond to a request for comment. To be sure, the New York-based hedge fund held just under half a million shares back in 2017 when Sage approached $100 per share after its lead asset saw success in another clinical trial.

  • Incyte (INCY) Q4 Earnings Lag Estimates
    Zacks2 days ago

    Incyte (INCY) Q4 Earnings Lag Estimates

    Incyte (INCY) delivered earnings and revenue surprises of -6.98% and 0.47%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 days ago

    Incyte: 4Q Earnings Snapshot

    The Wilmington, Delaware-based company said it had profit of 32 cents per share. Earnings, adjusted for stock option expense and amortization costs, were 40 cents per share. The results missed Wall Street ...

  • Business Wire2 days ago

    Incyte Reports 2018 Fourth Quarter and Year-End Financial Results, Provides 2019 Financial Guidance and Provides Updates on Key Clinical Programs

    WILMINGTON, Del.-- -- Total product-related revenues of $468 million in 4Q 2018 and $1.7 billion for the full year 2018 Jakafi ® revenues of $380 million in 4Q   2018 and $1.4 billion for the full year 2018 Multiple late-stage product candidates provide additional opportunities to further accelerate revenue growth Conference Call and Webcast Scheduled Today at 8:00 a.m. EST Incyte Corporation today ...

  • Investing.com3 days ago

    Incyte Earnings, Revenue beat in Q4

    Investing.com - Incyte (NASDAQ:INCY) reported fourth quarter earnings that beat analysts' expectations on Thursday and revenue that topped forecasts.

  • TheStreet.com3 days ago

    Incyte Expected to Earn 17 Cents a Share

    is expected to report earnings of 17 cents a share on sales of $486.2 million before the market opens Feb. 14, based on a FactSet survey of 10 analysts. The stock has risen 33.4% since the company last reported earnings on Oct. 30. Incyte is currently trading at a price-to-forward-earnings ratio of 56.1 based on the 12-month estimates of 19 analysts surveyed by FactSet.

  • Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars
    Zacks3 days ago

    Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars

    Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.

  • Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer
    Zacks4 days ago

    Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer

    Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.

  • Zacks.com featured highlights include: Incyte, First Majestic, Mattel and U.S. Silica
    Zacks4 days ago

    Zacks.com featured highlights include: Incyte, First Majestic, Mattel and U.S. Silica

    Zacks.com featured highlights include: Incyte, First Majestic, Mattel and U.S. Silica

  • Is a Disappointment in Store for Incyte (INCY) Q4 Earnings?
    Zacks5 days ago

    Is a Disappointment in Store for Incyte (INCY) Q4 Earnings?

    Investors are looking forward to Jakafi's performance and other pipeline updates when Incyte (INCY) reports Q4 results on Feb 14.

  • 4 Toxic Stocks to Abandon or Sell Short for Solid Gains
    Zacks5 days ago

    4 Toxic Stocks to Abandon or Sell Short for Solid Gains

    Overpriced toxic stocks are generally susceptible to external shocks and loaded with huge amount of debt.

  • Why Incyte Stock Gained 27% in January
    Motley Fool5 days ago

    Why Incyte Stock Gained 27% in January

    The biotech attracted more optimism from Wall Street ahead of its upcoming fourth-quarter report.

  • Incyte Down as FDA Extends Review Period of Jakafi for GVHD
    Zacks8 days ago

    Incyte Down as FDA Extends Review Period of Jakafi for GVHD

    The FDA extends the review period of Incyte's (INCY) sNDA for the label expansion of Jakafi for the treatment of acute GVHD.

  • Markit8 days ago

    See what the IHS Markit Score report has to say about Incyte Corp.

    Incyte Corp NASDAQ/NGS:INCYView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for INCY with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting INCY. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding INCY totaled $14.27 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • FDA Delays This Biotech's Drug — Why Analysts Are Still Bullish
    Investor's Business Daily9 days ago

    FDA Delays This Biotech's Drug — Why Analysts Are Still Bullish

    Incyte stock dipped Thursday after the Food and Drug Administration unexpectedly delayed its graft vs. host disease treatment by three months. The FDA is now set to review the drug in May.

  • FDA resets decision date on Incyte's GVHD treatment application
    American City Business Journals9 days ago

    FDA resets decision date on Incyte's GVHD treatment application

    A ruling on the Wilmington biotech company's supplemental application for Jakafi will occur in May.

  • Business Wire9 days ago

    Incyte Announces U.S. FDA Has Extended the Review Period for Ruxolitinib (Jakafi®) in Acute Graft-Versus-Host Disease

    Incyte (INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for ruxolitinib (Jakafi®) for the treatment of patients with acute graft-versus-host disease (GVHD) who have had an inadequate response to corticosteroids. The FDA extended the action date to allow time to review additional data submitted by Incyte in response to the FDA’s information requests. The submission of the additional information has been determined by the FDA to constitute a Major Amendment to the sNDA, resulting in an extension of the PDUFA goal date by three months.

  • MacroGenics stock spikes from positive results of cancer drug trial
    American City Business Journals10 days ago

    MacroGenics stock spikes from positive results of cancer drug trial

    The successful late-stage trial is a big victory for the Rockville biotech, which focuses on antibody-based therapeutics to treat cancer.

  • Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies
    Zacks11 days ago

    Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies

    Eli Lilly and Company (LLY) and partner Incyte's Olumiant meets primary endpoint in two phase III studies evaluating it for moderate-to-severe atopic dermatitis.

  • Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis
    PR Newswire12 days ago

    Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis

    INDIANAPOLIS, Feb. 4, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD1 and BREEZE-AD2, two Phase 3 studies evaluating the efficacy and safety of baricitinib monotherapy for the treatment of adult patients with moderate to severe atopic dermatitis (AD). In both investigational trials, compared to patients treated with placebo, a statistically significant proportion of patients treated with baricitinib achieved the primary endpoint at Week 16 defined by the Investigator's Global Assessment for AD (IGA) score of clear or almost clear (IGA 0,1). In the 16-week placebo-controlled phase of BREEZE-AD1 and BREEZE-AD2, the incidence of treatment-emergent adverse events and serious adverse events with baricitinib treatment was similar to placebo, and the most common treatment-emergent adverse events observed were nasopharyngitis and headache.

  • Zacks17 days ago

    Dow Pushes Forward Under Apple's Shadow

    Dow Pushes Forward Under Apple's Shadow

  • GlobeNewswire18 days ago

    Report: Developing Opportunities within Incyte, Burlington Stores, Hannon Armstrong Sustainable Infrastructure Capital, iRobot, Lear, and Menlo Therapeutics — Future Expectations, Projections Moving into 2019

    NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.